ArticlePLoS computational biology2017
Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence.
Article in PLoS computational biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis.Medical microbiology and immunology · 2019Pooled it
- Blood Donor Sex and Outcomes in Transfused Infants.Clinics in perinatology · 2023Review
- Development of a CRISPR-Cas12a rapid diagnostic for human cytomegalovirus.Antiviral research · 2023Article
- Therapeutic targeting of HCMV-encoded chemokine receptor US28: Progress and challenges.Frontiers in immunology · 2023Review
- The Association of Cytomegalovirus IgM and Allostatic Load.Diseases (Basel, Switzerland) · 2022Article
- Article
- Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.Nature communications · 2022Article
- Quantification of T-cell dynamics during latent cytomegalovirus infection in humans.PLoS pathogens · 2021Article
- Validation of Preamplification to Improve Quantification of Cytomegalovirus DNA Using Droplet Digital Polymerase Chain Reaction.Analytical chemistry · 2021Article
- Estimating the cumulative incidence of SARS-CoV-2 with imperfect serological tests: Exploiting cutoff-free approaches.PLoS computational biology · 2021Article
- Age and CMV-Infection Jointly Affect the EBV-Specific CD8Frontiers in aging · 2021Article
- A robust and interpretable end-to-end deep learning model for cytometry data.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Short- and long-term impact of vaccination against cytomegalovirus: a modeling study.BMC medicine · 2020Article
- Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Limited effect of duration of CMV infection on adaptive immunity and frailty: insights from a 27-year-long longitudinal study.Clinical & translational immunology · 2020Article
- Human Cytomegalovirus Infections Are Associated With Elevated Biomarkers of Vascular Injury.Frontiers in cellular and infection microbiology · 2020Article
- Correction: Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence.PLoS computational biology · 2019Article
- Integrating measures of viral prevalence and seroprevalence: a mechanistic modelling approach to explaining cohort patterns of human papillomavirus in women in the USA.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Article
- The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalence.Epidemiology and infection · 2019Article
- Six weeks of strength endurance training decreases circulating senescence-prone T-lymphocytes in cytomegalovirus seropositive but not seronegative older women.Immunity & ageing : I & A · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (CMV) is a herpes virus with poorly understood transmission dynamics. Person-to-person transmission is thought to occur primarily through transfer of saliva or urine, but no quantitative estimates are available for the contribution of different infection routes. Using data from a large population-based serological study (n = 5,179), we provide quantitative estimates of key epidemiological parameters, including the transmissibility of primary infection, reactivation, and re-infection. Mixture models are fitted to age- and sex-specific antibody response data from the Netherlands, showing that the data can be described by a model with three distributions of antibody measurements, i.e. uninfected, infected, and infected with increased antibody concentration. Estimates of seroprevalence increase gradually with age, such that at 80 years 73% (95%CrI: 64%-78%) of females and 62% (95%CrI: 55%-68%) of males are infected, while 57% (95%CrI: 47%-67%) of females and 37% (95%CrI: 28%-46%) of males have increased antibody concentration. Merging the statistical analyses with transmission models, we find that models with infectious reactivation (i.e. reactivation that can lead to the virus being transmitted to a novel host) fit the data significantly better than models without infectious reactivation. Estimated reactivation rates increase from low values in children to 2%-4% per year in women older than 50 years. The results advance a hypothesis in which transmission from adults after infectious reactivation is a key driver of transmission. We discuss the implications for control strategies aimed at reducing CMV infection in vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.